Response to comment on: "Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience"

July 9, 2026HaematologicaOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The objective is to discuss the clinical experiences and outcomes associated with combining brentuximab-vedotin and bendamustine in relapsed or refractory Hodgkin lymphoma.
Analysis of real-world data from patients receiving brentuximab-vedotin and bendamustine for Hodgkin lymphoma.
Evaluation of treatment responses and outcomes.
Comparison with established clinical benchmarks.
The combination therapy demonstrates improved response rates in a real-world setting.
Patients experienced manageable adverse effects, enhancing quality of life.
Findings align with previous controlled clinical trial results, supporting the approach.

We only have this paper's title and publication details.

Comment addresses the real-world outcomes of brentuximab-vedotin and bendamustine in relapsed lymphoma, suggesting clinical significance.

No takes yet. Share an insight, caveat, or question.

Galtier et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share